BioMarin reports Q4 non-GAAP EPS 49c, consensus 23c

Reports Q4 revenue $646.2M, consensus $636.88M. “Strong financial results in 2023 were driven by global demand for VOXZOGO, the only approved treatment for children with achondroplasia, and contributions from our established enzyme products. Voxzogo revenues grew 18% over the prior quarter and were positively impacted by an increase in prescriptions for children in the United States under the age of 5, following the FDA’s October approval of Voxzogo for children of all ages with open growth plates,” said CEO Alexander Hardy. “Looking ahead in 2024, our full-year financial guidance reflects our focus on value creation through achievement of four strategic priorities outlined earlier this year. We intend to maximize the Voxzogo opportunity, continue to build-out global access channels for Roctavian, judiciously prioritize the most potentially impactful R&D candidates, and drive operational excellence and cost optimization with the goal of delivering growth, efficiency and profitability.”